Skip to main content
Dryad

Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153,000 patients

Data files

May 31, 2021 version files 413.91 KB

Abstract

Objective: To estimate relative risk of statin-associated musculoskeletal symptoms (SAMS) by statin therapy intensity. Setting: Network meta-analysis assessing multi-center RCTs across several countries. Participants: Pubmed, Web of Science, Cochrane database, and clinicaltrials.gov were searched through January 2021 for doubled-blinded RCTs testing the effect of statin therapy on lipids with at least 1000 participants and two years of intended treatment. Two coders assessed articles for final inclusion, quality, and outcomes. Treatment intensity was categorized according to American Heart Association definitions.

Outcomes: Pairwise and network meta-analysis (NMA) estimated relative risk (RR) and risk difference (RD) with random effects modeling. Heterogeneity was evaluated with the I2 statistic. Outcomes included muscle symptoms (any, myalgia, and attrition due to muscle symptoms), rhabdomyolysis, and elevated creatine kinase (>10x upper limit of normal).

Results: Of 2801 RCTs, 24 (N=152,461) met inclusion criteria. NMA results indicated risk was significantly greater for high compared to moderate intensity statin therapy for any muscle problem (RR=1.04, 95% CI: 1.00,1.07; I2=0% ), myalgia (RR=1.04, 95% CI: 1.00,1.08; I2=0%, NNH=173), attrition due to muscle problems (RR=1.37, 95% CI: 1.09,1.73, I2=0%, NNH=218), and elevated CK (RR=4.69, CI: 2.50, 8.80; I2=7%, NNH=527). Risk also was significantly higher for high intensity compared to placebo for any muscle problem (RR=1.05, 95% CI: 1.01,1.09, I2=0% ), myalgia (RR=1.13, 95% CI: 1.05,1.23; I2=0%, NNH=182), attrition due to muscle problems (RR=1.55, 95% CI: 1.15,2.08, I2=0%, NNH=187), and elevated CK (RR=5.37, CI: 2.48, 11.61; I2=7%, NNH=589). Due to inconsistency of results across sensitivity analyses, estimates were inconclusive for rhabdomyolysis and CK. There were no significant differences in risk between moderate-intensity therapy and placebo for all outcomes.

Conclusions: For approximately 200 patients on high-intensity statins, one additional patient may experience myalgia or discontinue therapy due to muscle problems compared to moderate-intensity therapy.

Trial Registration: Prospero #CRD42019112758